1260 Results for "

CDKs

" in MedChemExpress (MCE) Product Catalog:
Products (1260)

1260 Results for "CDKs" in MCE Product Catalog:

7
7 Cited Publications
Cat. No.: HY-15004
CAS No.: 853299-07-7
Purity:  99.15%
Synonyms: K03861
Target:  

CDK

Research Areas:  

Cancer

AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-16462
CAS No.: 1263369-28-3
Target:  

CDK

Research Areas:  

Cancer

CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-N1127
CAS No.: 520-32-1
Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128587
CAS No.: 1816989-16-8
Purity:  98.02%
Synonyms: SY-1365
Target:  

CDK

Research Areas:  

Cancer

Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-101212
CAS No.: 1070790-89-4
Purity:  99.50%
Synonyms: CYC065
Target:  

CDK

Research Areas:  

Cancer

Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50s of 5 and 26 nM, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-129336
CAS No.: 2138499-06-4
Purity:  96.02%
Synonyms: LSN3106726
Target:  

CDK

Research Areas:  

Cancer

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12280
CAS No.: 1604810-84-5
Purity:  99.03%
Target:  

CDK

Research Areas:  

Cancer

THZ2 is a potent and selective CDK7 inhibitor with an IC50 of 13.9 nM.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10542
CAS No.: 220904-83-6
Purity:  99.49%
Target:  

Raf Apoptosis

Research Areas:  

Cancer

GW 5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-162001
CAS No.: 2745060-92-6
Target:  

CDK

Research Areas:  

Cancer

INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15166B
CAS No.: 1204918-73-9
Purity:  98.06%
Synonyms: (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0260
CAS No.: 110642-44-9
Synonyms: Epimedin-C; Baohuoside-VI
Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of CDK2/Cyclin E. Epmedin C also upregulates Nrf2 expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-126675A
CAS No.: 2241300-51-4
Purity:  99.94%
Research Areas:  

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-126675
CAS No.: 2241300-50-3
Purity:  99.68%
Research Areas:  

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15166
CAS No.: 937270-47-8
Purity:  99.70%
Synonyms: (E/Z)-TG02; (E/Z)-SB1317
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15166A
CAS No.: 1321626-25-8
Purity:  99.90%
Synonyms: (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib ((E/Z)-TG02) is an orally active inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0636
CAS No.: 13463-28-0
Synonyms: Eriodictyol 7-rutinoside; Eriodictyol 7-O-rutinoside
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0417
CAS No.: 18444-66-1
Synonyms: α-Elaterin; α-Elaterine
Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the cyclin B1/CDC2 complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-112457
CAS No.: 1186648-22-5
Purity:  98.03%
Target:  

MAPKAPK2 (MK2)

Research Areas:  

Inflammation/Immunology

MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 8.5 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC50=0.21 μM), MK-5 (IC50=0.081 μM), ERK2 (IC50=3.44 μM), MNK1(IC50=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-131249
CAS No.: 724711-21-1
Purity:  99.15%
Target:  

MAPKAPK2 (MK2)

Research Areas:  

Inflammation/Immunology

MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-18629
CAS No.: 377090-84-1
Target:  

CDK Autophagy Apoptosis

Research Areas:  

Cancer

SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.
loading...
    loading...